Novel incretin analogues improve autophagy and protect from mitochondrial stress induced by rotenone in SH‐SY 5Y cells
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
Currently, there is no viable treatment available for Parkinson's disease (PD) that stops or reverses disease progression. Interestingly, studies testing the glucagon‐like‐peptide‐1 (GLP‐1) mimetic Exendin‐4 have shown neuroprotective/neurorestorative properties in pre‐clinical tests and in a pilot clinical study of PD. Incretin analogues were originally developed to treat type 2 diabetes and several are currently on the market. In this study, we tested novel incretin analogues on the dopaminergic SH‐SY 5Y neuroblastoma cells against a toxic mitochondrial complex I inhibitor, Rotenone. Here, we investigate for the first time the effects of six different incretin receptor agonists – Liraglutide, D‐Ser2‐Oxyntomodulin, a GLP‐1/GIP Dual receptor agonist,dA la(2)‐GIP‐GluPal, Val(8)GLP‐1‐GluPal and exendin‐4. Post‐treatment with doses of 1, 10 or 100 nM of incretin analogues for 12 h increased the survival of SH‐SY 5Y cells treated with 1 μM Rotenone for 12 h. Furthermore, we studied the post‐treatment effect of 100 nM incretin analogues against 1 μM Rotenone stress on apoptosis, mitochondrial stress and autophagy markers. We found significant protective effects of the analogues against Rotenone stress on cell survival and on mitochondrial and autophagy‐associated markers. The novel GLP‐1/GIP Dual receptor agonist was superior and effective at a tenfold lower concentration compared to the other analogues. Using the Phosphatidylinositol 3‐kinase (PI 3K) inhibitor,LY 294002, we further show that the neuroprotective effects are partially PI 3K‐independent. Our data suggest that the neuroprotective properties exhibited by incretin analogues against Rotenone stress involve enhanced autophagy, increased Akt‐mediated cell survival and amelioration of mitochondrial dysfunction. These mechanisms can explain the neuroprotective effects of incretin analogues reported in clinical trials. imageGLP‐1,GIP and dual incretin receptor agonists showed protective effects in SH‐SY 5Y cells treated with the stressor Rotenone. The novel GLP‐1/GIP dual receptor agonist was superior and effective at a tenfold lower concentration compared to the other analogues. The drugs protected the cells from rotenone‐induced impairment in cell growth and Akt activation, mitochondrial damage, impairments of autophagy and apoptotic cell signalling. See paper for details.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Role of Atg Proteins in Autophagosome Formation
Mizushima, N., Yoshimori, T., & Ohsumi, Y. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154005 · Cited by 2,978
The Beclin 1 network regulates autophagy and apoptosis
Kang, R., Zeh, H. J., Lotze, M. T., & Tang, D. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2010.191 · Cited by 2,485
The role of autophagy in neurodegenerative disease
Nixon, R. A. (2013) · Nature Medicine · doi:10.1038/nm.3232 · Cited by 2,059
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500
Mitochondria in innate immune responses
West, A. P., Shadel, G. S., & Ghosh, S. (2011) · Nature Reviews Immunology · doi:10.1038/nri2975 · Cited by 1,376
Autophagy and apoptosis dysfunction in neurodegenerative disorders
Ghavami, S., Shojaei, S., Yeganeh, B., Ande, S. R., Jangamreddy, J. R., Mehrpour, M., Christoffersson, J., Chaabane, W., Moghadam, A. R., Kashani, H. H., et al. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.10.004 · Cited by 1,039 · cited 2×
“Autophagy and apoptosis are the two basic processes contributing to the maintenance of cellular homeostasis (Ghavami et al. 2014).”
BackgroundEndoplasmic reticulum-mitochondria contacts: Function of the junction
Rowland, A. A., & Voeltz, G. K. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3440 · Cited by 1,018
Parkinson’s disease: genetics and pathogenesis
Shulman, J. M., De Jager, P. L., & Feany, M. B. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130242 · Cited by 801
McClean, P. L., Parthsarathy, V., Faivre, E., & Hölscher, C. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.0529-11.2011 · Cited by 698
Self-citationUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 4×
“The effective dose of the dual agonist was far lower compared to liraglutide, a finding that we confirmed in this in vitro study (Finan et al. 2013).”
BackgroundResultInfluentialMitochondrial dysfunction in Parkinson's disease
Winklhofer, K. F., & Haass, C. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.013 · Cited by 688
Li, Y., Perry, T., Kindy, M. S., Harvey, B. K., Tweedie, D., Holloway, H. W., Powers, K., Shen, H., Egan, J. M., Sambamurti, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806720106 · Cited by 589 · cited 2×
“Further studies also show that Exendin-4 protects dopaminergic neurons (Kim et al. 2009; Li et al. 2009).”
BackgroundGejl, M., Gjedde, A., Egefjord, L., Møller, A., Hansen, S. B., Vang, K., Rodell, A., Brændgaard, H., Gottrup, H., Schacht, A., et al. (2016) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2016.00108 · Cited by 480
Type 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Bertilsson, G., Patrone, C., Zachrisson, O., Andersson, A., Dannaeus, K., Heidrich, J., Kortesmaa, J., Mercer, A., Nielsen, E., Rönnholm, H., et al. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21483 · Cited by 345
Sharma, S., Mells, J. E., Fu, P. P., Saxena, N. K., & Anania, F. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025269 · Cited by 272 · cited 1×
“Both Exendin-4 and Liraglutide reduce hepatocyte steatosis and improve survival by promotingmacro-autophagy (Sharma et al. 2011).”
BackgroundKim, S., Moon, M., & Park, S. (2009) · Journal of Endocrinology · doi:10.1677/joe-09-0132 · Cited by 263 · cited 1×
“Further studies also show that Exendin-4 protects dopaminergic neurons (Kim et al. 2009; Li et al. 2009).”
BackgroundLiu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246 · cited 3×
“Liraglutide and other GLP-1 mimetics showed good protective effects in the 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD (Liu et al. 2015b).”
BackgroundSelf-citationSharma, M. K., Jalewa, J., & Hölscher, C. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12469 · Cited by 151
Self-citationMartin, C. M. A., Irwin, N., Flatt, P. R., & Gault, V. A. (2013) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2013.03.011 · Cited by 53
Cited by
Brain energy rescue: an emerging therapeutic concept for neurodegenerative disorders of ageing
Cunnane, S. C., Trushina, E., Morland, C., Prigione, A., Casadesus, G., Andrews, Z. B., Beal, M. F., Bergersen, L. H., Brinton, R. D., de la Monte, S., et al. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0072-x · Cited by 1,003
The Role of Autophagy in Parkinson's Disease
Lynch-Day, M. A., Mao, K., Wang, K., Zhao, M., & Klionsky, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009357 · Cited by 458
Insulin resistance and Parkinson’s disease: A new target for disease modification?
Athauda, D., & Foltynie, T. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.10.001 · Cited by 328
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Self-citationBrain insulin resistance: role in neurodegenerative disease and potential for targeting
Hölscher, C. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1738383 · Cited by 180
Self-citation
Metadata
- Authors
- Jalewa, J., Sharma, M. K., & Hölscher, C.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2016-08-24
- Volume
- 139
- Issue
- 1
- Pages
- 55-67
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W2468864843
- Cited by
- 73
- References
- 20
- FWCI
- 7.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.